WNT Signaling in Cancer Immunosurveillance

Lorenzo Galluzzi; Stefani Spranger; Elaine Fuchs; Alejandro López-Soto

doi:10.1016/j.tcb.2018.08.005

WNT Signaling in Cancer Immunosurveillance

Lorenzo Galluzzi, Stefani Spranger, Elaine Fuchs, Alejandro López-Soto

Research output: Contribution to journal › Review article › peer-review

171 Scopus citations

Abstract

Deregulated WNT signaling has been shown to favor malignant transformation, tumor progression, and resistance to conventional cancer therapy in a variety of preclinical and clinical settings. Accumulating evidence suggests that aberrant WNT signaling may also subvert cancer immunosurveillance, hence promoting immunoevasion and resistance to multiple immunotherapeutics, including immune checkpoint blockers. Here, we discuss the molecular and cellular mechanisms through which WNT signaling influences cancer immunosurveillance and present potential therapeutic avenues to harness currently available WNT modulators for cancer immunotherapy.

Original language	English
Pages (from-to)	44-65
Number of pages	22
Journal	Trends in Cell Biology
Volume	29
Issue number	1
DOIs	https://doi.org/10.1016/j.tcb.2018.08.005
State	Published - Jan 2019
Externally published	Yes

Keywords

BRAF
cancer immunotherapy
CTLA4
GSK3
PD-L1/PD-1 axis
tumor microenvironment
β-catenin

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.tcb.2018.08.005

Cite this

@article{bc269814464c4f5abfa7232e5029e222,

title = "WNT Signaling in Cancer Immunosurveillance",

abstract = "Deregulated WNT signaling has been shown to favor malignant transformation, tumor progression, and resistance to conventional cancer therapy in a variety of preclinical and clinical settings. Accumulating evidence suggests that aberrant WNT signaling may also subvert cancer immunosurveillance, hence promoting immunoevasion and resistance to multiple immunotherapeutics, including immune checkpoint blockers. Here, we discuss the molecular and cellular mechanisms through which WNT signaling influences cancer immunosurveillance and present potential therapeutic avenues to harness currently available WNT modulators for cancer immunotherapy.",

keywords = "BRAF, cancer immunotherapy, CTLA4, GSK3, PD-L1/PD-1 axis, tumor microenvironment, β-catenin",

author = "Lorenzo Galluzzi and Stefani Spranger and Elaine Fuchs and Alejandro L{\'o}pez-Soto",

note = "Publisher Copyright: {\textcopyright} 2018 Elsevier Ltd",

year = "2019",

month = jan,

doi = "10.1016/j.tcb.2018.08.005",

language = "English",

volume = "29",

pages = "44--65",

journal = "Trends in Cell Biology",

issn = "0962-8924",

publisher = "Elsevier Ltd.",

number = "1",

}

TY - JOUR

T1 - WNT Signaling in Cancer Immunosurveillance

AU - Galluzzi, Lorenzo

AU - Spranger, Stefani

AU - Fuchs, Elaine

AU - López-Soto, Alejandro

PY - 2019/1

Y1 - 2019/1

N2 - Deregulated WNT signaling has been shown to favor malignant transformation, tumor progression, and resistance to conventional cancer therapy in a variety of preclinical and clinical settings. Accumulating evidence suggests that aberrant WNT signaling may also subvert cancer immunosurveillance, hence promoting immunoevasion and resistance to multiple immunotherapeutics, including immune checkpoint blockers. Here, we discuss the molecular and cellular mechanisms through which WNT signaling influences cancer immunosurveillance and present potential therapeutic avenues to harness currently available WNT modulators for cancer immunotherapy.

AB - Deregulated WNT signaling has been shown to favor malignant transformation, tumor progression, and resistance to conventional cancer therapy in a variety of preclinical and clinical settings. Accumulating evidence suggests that aberrant WNT signaling may also subvert cancer immunosurveillance, hence promoting immunoevasion and resistance to multiple immunotherapeutics, including immune checkpoint blockers. Here, we discuss the molecular and cellular mechanisms through which WNT signaling influences cancer immunosurveillance and present potential therapeutic avenues to harness currently available WNT modulators for cancer immunotherapy.

KW - BRAF

KW - cancer immunotherapy

KW - CTLA4

KW - GSK3

KW - PD-L1/PD-1 axis

KW - tumor microenvironment

KW - β-catenin

UR - http://www.scopus.com/inward/record.url?scp=85053106563&partnerID=8YFLogxK

U2 - 10.1016/j.tcb.2018.08.005

DO - 10.1016/j.tcb.2018.08.005

M3 - Review article

C2 - 30220580

AN - SCOPUS:85053106563

SN - 0962-8924

VL - 29

SP - 44

EP - 65

JO - Trends in Cell Biology

JF - Trends in Cell Biology

IS - 1

ER -

WNT Signaling in Cancer Immunosurveillance

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this